Heidi Taipale1,2,3, Anna-Maija Tolppanen2,4, Miia Tiihonen1,2, Antti Tanskanen3,5,6, Jari Tiihonen3,5, Sirpa Hartikainen1,2,7. 1. Kuopio Research Centre of Geriatric Care, University of Eastern Finland, Kuopio, Finland. 2. School of Pharmacy, University of Eastern Finland, Kuopio, Finland. 3. Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Kuopio, Finland. 4. Research Centre for Comparative Effectiveness and Patient Safety (RECEPS), University of Eastern Finland, Kuopio, Finland. 5. Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. 6. National Institute for Health and Welfare, Helsinki, Finland. 7. Department of Psychiatry, Kuopio University Hospital, Kuopio, Finland.
Abstract
OBJECTIVES: The objective of the study was to investigate whether proton pump inhibitor (PPI) use is associated with an increased risk of clinically verified Alzheimer's disease (AD). METHODS: A Finnish nationwide nested case-control study MEDALZ includes all community-dwelling individuals with newly diagnosed AD during 2005-2011 (N=70,718), and up to four age-, sex-, and region of residence-matched comparison individuals for each case (N=282,858). Data were extracted from Finnish nationwide health-care registers. PPI use was derived from purchases recorded in the Prescription register data since 1995 and modeled to drug use periods with PRE2DUP method. AD was the outcome measure. RESULTS: PPI use was not associated with risk of AD with 3-year lag window applied between exposure and outcome (adjusted odds ratio (OR) 1.03, 95% confidence interval (CI) 1.00-1.05). Similarly, longer duration of use was not associated with risk of AD (1-3 years of use, adjusted OR 1.01 (95% CI 0.97-1.06); ≥3 years of use adjusted OR 0.99 (95% CI 0.94-1.04)). Higher dose use was not associated with an increased risk (≥1.5 defined daily doses per day, adjusted OR 1.03 (95% CI 0.92-1.14)). CONCLUSIONS: In conclusion, we found no clinically meaningful association between PPI use and risk of AD. The results for longer duration of cumulative use or use with higher doses did not indicate dose-response relationship.
OBJECTIVES: The objective of the study was to investigate whether proton pump inhibitor (PPI) use is associated with an increased risk of clinically verified Alzheimer's disease (AD). METHODS: A Finnish nationwide nested case-control study MEDALZ includes all community-dwelling individuals with newly diagnosed AD during 2005-2011 (N=70,718), and up to four age-, sex-, and region of residence-matched comparison individuals for each case (N=282,858). Data were extracted from Finnish nationwide health-care registers. PPI use was derived from purchases recorded in the Prescription register data since 1995 and modeled to drug use periods with PRE2DUP method. AD was the outcome measure. RESULTS: PPI use was not associated with risk of AD with 3-year lag window applied between exposure and outcome (adjusted odds ratio (OR) 1.03, 95% confidence interval (CI) 1.00-1.05). Similarly, longer duration of use was not associated with risk of AD (1-3 years of use, adjusted OR 1.01 (95% CI 0.97-1.06); ≥3 years of use adjusted OR 0.99 (95% CI 0.94-1.04)). Higher dose use was not associated with an increased risk (≥1.5 defined daily doses per day, adjusted OR 1.03 (95% CI 0.92-1.14)). CONCLUSIONS: In conclusion, we found no clinically meaningful association between PPI use and risk of AD. The results for longer duration of cumulative use or use with higher doses did not indicate dose-response relationship.
Authors: L Fratiglioni; L J Launer; K Andersen; M M Breteler; J R Copeland; J F Dartigues; A Lobo; J Martinez-Lage; H Soininen; A Hofman Journal: Neurology Date: 2000 Impact factor: 9.910
Authors: Sophie Billioti de Gage; Yola Moride; Thierry Ducruet; Tobias Kurth; Hélène Verdoux; Marie Tournier; Antoine Pariente; Bernard Bégaud Journal: BMJ Date: 2014-09-09
Authors: Shelly L Gray; Sascha Dublin; Onchee Yu; Rod Walker; Melissa Anderson; Rebecca A Hubbard; Paul K Crane; Eric B Larson Journal: BMJ Date: 2016-02-02
Authors: Taylor J Krivanek; Seth A Gale; Brittany M McFeeley; Casey M Nicastri; Kirk R Daffner Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Hyo Geun Choi; Joo-Hee Kim; Ji Hee Kim; Eun Soo Kim; Ha Young Park; Kyueng-Whan Min; Mi Jung Kwon Journal: Alzheimers Res Ther Date: 2022-07-01 Impact factor: 8.823